Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Anorectic drugs: use in general practice

D Craddock

    Drugs
    |January 1, 1976
    PubMed
    Summary
    This summary is machine-generated.

    Anorectic drugs aid obesity treatment by targeting the brain's satiety center. Diethylpropion is recommended as a first-choice option due to its efficacy and safety profile compared to other appetite suppressants.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    A Report by a Therapeutic Study Group.

    The Journal of the College of General Practitioners·2009
    Same author

    Factors influencing mortality and myocardial infarction after coronary artery bypass grafting.

    Current opinion in cardiology·1994
    Same author

    Mortality and myocardial infarction after coronary artery surgery. A review of 12,003 patients.

    The Medical journal of Australia·1993
    Same author

    Quinine for night cramps.

    The British journal of general practice : the journal of the Royal College of General Practitioners·1993
    Same author

    Effect of 6 months therapy with dexfenfluramine in obese patients: studies in the United Kingdom.

    Clinical neuropharmacology·1988
    Same author

    Prolonged weight loss with dexfenfluramine treatment in obese patients.

    Diabete & metabolisme·1987
    Same journal

    Ecnoglutide: First Approvals.

    Drugs·2026
    Same journal

    The Long Road to Long-Acting: What Oral PrEP and CAB-LA Teach Us About Scaling Lenacapavir.

    Drugs·2026
    Same journal

    Botulinum Toxin Type A for Trigeminal and Postherpetic Neuralgia: An Umbrella Review of Systematic Reviews.

    Drugs·2026
    Same journal

    Biologics and Small Molecule Inhibitors: Novel Therapeutic Strategies for Cutaneous Adverse Drug Reactions.

    Drugs·2026
    Same journal

    Use of Sedative-Hypnotic Drugs and the Risk of Developing Alzheimer's Disease: A Systematic Review, Meta-Analysis and Meta-Regression.

    Drugs·2026
    Same journal

    Relacorilant: First Approval.

    Drugs·2026
    See all related articles

    Area of Science:

    • Pharmacology and Preventive Medicine
    • Endocrinology and Metabolic Disorders

    Background:

    • Obesity is a significant public health concern, contributing to the "coronary epidemic" and increasing the risk of maturity-onset diabetes.
    • Effective obesity treatment is crucial for preventive medicine, impacting cardiovascular health and metabolic disease prevention.

    Purpose of the Study:

    • To review the efficacy and safety of various anorectic drugs used in obesity management.
    • To identify the most suitable anorectic medications for patients with persistent weight loss plateaus.

    Main Methods:

    • Review of anorectic drugs, primarily amphetamine derivatives, acting on the hypothalamus satiety center.
    • Analysis of drug mechanisms, including effects on metabolism, physical activity, and potential central nervous system alterations.

    Related Experiment Videos

  • Evaluation of side effects, addiction potential, drug interactions, and long-term safety profiles.

    • Main Results:

    • Anorectic drugs can be effective, especially for individuals plateauing in weight loss despite dietary changes.
    • Common side effects include central nervous system stimulation (except fenfluramine) and gastrointestinal irritation.
    • High addiction potential exists for dexamphetamine, phenmetrazine, and benzphetamine; chlorphentermine poses long-term risks.

    Conclusions:

    • Diethylpropion is identified as the first-choice anorectic due to a favorable balance of efficacy and safety.
    • Fenfluramine may be useful for tense individuals or obese diabetics unresponsive to biguanides, despite potential depression and side effects.
    • Careful clinical supervision is essential for safe and effective use of anorectic drugs, particularly in long-acting formulations.